EX-16.1 2 exh_161.htm EXHIBIT 16.1








March 26, 2018



Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549




We have read the statements made by Cytokinetics, Inc. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K, as part of the Form 8-K of Cytokinetics dated March 21, 2018. We agree with the statements concerning our Firm contained therein.


Very truly yours,




/s/ PricewaterhouseCoopers LLP

San Jose, CA



Attachment – Form 8-K